Life Science Investing First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Life Science Investing SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Life Science Investing SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
Life Science Investing SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
Life Science Investing SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
Life Science Investing SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
LAURION Intersects High-Grade Gold, Silver and Zinc at Ishkoday A-Zone/McLeod/CRK Zone, Confirming Structural Continuity Along Mineralized Corridor
